Lymphoma, B-Cell Clinical Trials

144 clinical trials for Lymphoma, B-Cell across international registries, including 18 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy — RECRUITING · PHASE3
• Phase 1 Trial of BTM-3566 in Relapsed/Refractory Mature B Cell Lymphomas — RECRUITING · PHASE1
• A Phase 1/2 Study of STP938 (Dencatistat) for Adult Subjects With Relapsed/Refractory B-Cell and T-Cell Lymphomas — RECRUITING · PHASE1
• A Phase 1 Study of UB-VV111 With and Without Rapamycin in Relapsed/Refractory CD19+ B-cell Malignancies — RECRUITING · PHASE1
• Defining ctDNA Metrics in Posttransplant Lymphoproliferative Disorder (PTLD) — RECRUITING · PHASE2
• Study of CAR-T Therapy in Older Patients — RECRUITING
• ctDNA-guided Therapy Optimization in Newly Diagnosed DLBCL — RECRUITING · NA
• Early Palliative Care for Patients With Multiple Myeloma and Aggressive Lymphoma — RECRUITING · NA
• Family Study of Lymphoproliferative Disorders — RECRUITING
• Study of a Communication Training Intervention for Large B-Cell Lymphoma Providers — RECRUITING · NA
• Early Assessment of Cardiac Function After Treatment With CAR-T Cells — RECRUITING
• Prospective Observational Study of Diffuse Large-cell B Lymphoma — RECRUITING
• A Phase I/II Trial of ALETA-001 for the Treatment of Participants With B-cell Malignancies — RECRUITING · PHASE1
• CD-19 CAR-T Cell for Pediatric ALL or Lymphoma — RECRUITING · NA
• CD30 CAR-T in the Treatment of CD30 Positive Relapsed/Refractory Lymphoma — RECRUITING · NA
• Phase Ib Clinical Study of Keynatinib — RECRUITING · PHASE1
• Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies — RECRUITING · PHASE1
• Axicabtagene Ciloleucel for Consolidation After First-line Treatment of High-risk Large B-cell Lymphoma — RECRUITING · PHASE4
• Administration of Anti-CD19-chimeric-antigen-receptor-transduced T Cells From the Original Transplant Donor to Patients With Recurrent or Persistent B-cell Malignancies After Allogeneic Stem Cell Transplantation — COMPLETED · PHASE1
• A Study of JNJ-90014496 in Participants With B-Cell Non-Hodgkin Lymphoma — ACTIVE_NOT_RECRUITING · PHASE1
• Anti-CD19 CAR-T Cells With Inducible Caspase 9 Safety Switch for B-cell Lymphoma — ACTIVE_NOT_RECRUITING · PHASE1
• A Phase 1/2 Study of UB-VV400 With Rapamycin in Relapsed/Refractory B-cell Malignancies — NOT_YET_RECRUITING · PHASE1
• Study to Evaluate the Safety and Efficacy of a Combination of Favezelimab (MK-4280) and Pembrolizumab (MK-3475) in Participants With Hematologic Malignancies (MK-4280-003) — TERMINATED · PHASE1
• Retreatment With CTL019/CTL119 — WITHDRAWN · PHASE1
• Study of Safety and Efficacy of Iberdomide (CC-220) and CC-99282 Combined With R-CHOP to Treat Lymphoma — ACTIVE_NOT_RECRUITING · PHASE1
• Trial of Anti-CD19 and Anti-CD20 Bicistronic Chimeric Antigen Receptor T Cells for Treating B-Cell Malignancies — ACTIVE_NOT_RECRUITING · PHASE1
• Phase I Master Protocol of Novel Combination Therapy for Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma — ACTIVE_NOT_RECRUITING · PHASE1
• A Study of Nemtabrutinib (MK-1026) in Participants With Relapsed or Refractory Hematologic Malignancies (ARQ 531-101/MK-1026-001) — ACTIVE_NOT_RECRUITING · PHASE1
• Clinical Study of CAR-T Cell Therapy Following ASCT for R/R B-cell Non-Hodgkin's Lymphoma — TERMINATED · PHASE2
• TPG: Tafasitamab, Polatuzumab Vedotin, and Glofitamab as First-line Therapy for Diffuse Large B-cell Lymphoma and High-grade B-cell Lymphoma — NOT_YET_RECRUITING · PHASE2
• FT819 in Subjects With B-cell Malignancies — ACTIVE_NOT_RECRUITING · PHASE1
• A Study of Melphalan in People With Lymphoma Getting an Autologous Hematopoietic Cell Transplant — ACTIVE_NOT_RECRUITING · PHASE1
• Study of Valemetostat Tosylate as a Single Agent in Patients With Relapse/Refractory B-cell Lymphoma — ACTIVE_NOT_RECRUITING · PHASE2
• A Study of LOXO-305 in Chinese Participants With Blood Cancer (Including Lymphoma and Chronic Leukemia) — COMPLETED · PHASE2
• Observational Study of People Living With HIV Treated With CD19-directed CAR T Cell — COMPLETED
• A Study of Polatuzumab Vedotin, Rituximab and Dose Attenuated CHP in Older Patients With DLBCL — ACTIVE_NOT_RECRUITING · PHASE2
• Adaptive Bridging RT in R/R B-cell Lymphoma (Pre-CAR T) — COMPLETED · NA
• STAY-STRONG Study of Exercise Training During Chemotherapy — COMPLETED · NA
• Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib. — ACTIVE_NOT_RECRUITING · PHASE4
• A Study of Two Associations of Rituximab and Chemotherapy, With a PET-driven Strategy, in Lymphoma — COMPLETED · PHASE2
• Pembrolizumab in Combination With Chemotherapy for Patients With Untreated B Cell Lymphoma — ACTIVE_NOT_RECRUITING · PHASE2
• A Phase I Trial of Donor- Derived 19-28z CAR T Cells Following Allogeneic Transplant for the Treatment of CD19 Malignancies — WITHDRAWN · PHASE1
• PD-1, LAG-3 and TIM-3 Checkpoint Blockade in DLBCL — WITHDRAWN · PHASE1
• A Study of Pembrolizumab (MK-3475) in Participants With Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma (rrPMBCL) (MK-3475-A33/KEYNOTE-A33) — COMPLETED · PHASE1
• A Safety Trial of Lisocabtagene Maraleucel (JCAR017) for Relapsed and Refractory (R/R) B-cell Non-Hodgkin Lymphoma (NHL) in the Outpatient Setting (TRANSCEND-OUTREACH-007) — COMPLETED · PHASE2
• QUILT-3.061: CD19 t-haNK in Subjects With Diffuse Large B-Cell Lymphoma — WITHDRAWN · PHASE1
• C752 for Refractory/Relapsed B Cell Non-Hodgkin Lymphoma — TERMINATED · PHASE1
• Sepantronium Bromide for the Treatment of High-grade B-cell Lymphoma — ACTIVE_NOT_RECRUITING · PHASE2
• CAR-37 T Cells in Hematologic Malignancies — COMPLETED · PHASE1
• A Real-World Study on Extranodal Lymphoma — NOT_YET_RECRUITING

Refine this search